Oncoinvent with new production facility at Nydalen

Our portfolio company Oncoinvent opened brand-new lab and production facilities at Nydalen Oslo. Now they control the whole production line of their lead product candidate Radspherin.


2017 has been a good year for Oncoinvent. The company has relocated and built new office and laboratory facilities, grown from four to twelve employees, and raised new capital. CEO at Oncoinvent Jan A. Alfheim believes that this represents a significant milestone for the company and will enable to further develop Radspherin®, a novel alpha-emitting radioactive microparticle designed for treatment of metastatic cancers in body cavities.

Oncoinvent ends the year in fashion by opening brand new laboratory and production facilities. A lot of interested investors came to tour the new facilities, observing an impressive lab with special infrastructure. Treating radioactivity, and circulating air in a facility that treats radioactive materials, calls for an extra advanced ventilation system.


Lab With all the Facilities
The idea of the new lab and research facility is to be able to contain the whole production line, from research to drug manufacturing, to one location. All this contained in an area of 581 m2.

Creating a modern lab with the capabilities to treat radioactive materials in an active and well populated part of Oslo demands very strict guidelines. The production suites in the facility are constructed to be qualified for Good Manufacturing Practice (GMP) for production of Medical Product Candidates. Systems for purifying and monitoring of air and water quality as well as the removal of any potential radioactivity have been installed to ensure the safety of the operators, population and the environment.

The Production and Research areas of the laboratory will facilitate both the development of the Radspherin program and other discovery projects of the Company.


A Weapon for Precision Medicine
Radspherin® has been shown to cause a significant reduction in tumor growth in preclinical studies  an it is anticipated that the product can potentially treat several forms of metastatic cancer, primarily in peritoneal carcinomatosis originating from ovarian cancer. Oncoinvent is developing Radspherin® as a ready-to-use injectable product that seeks out cancer tumors and destroys them from inside by emitting its radioactive content.

The first clinical indication for Radspherin® will be treatment of peritoneal carcinomatosis, a rare type of cancer that occurs in the peritoneum, the thin layer of tissue that covers abdominal organs and surrounds the abdominal cavity. Additionally, Oncoinvent has lined up a collaboration with European and American clinical research centers for the clinical development Radspherin®.


Source: Oslo Cancer Cluster